Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairment

Brain, Behavior, and Immunity

Volumn 33, Issue , 2013, Pages 183-189

  Lindqvist, Daniel ^a,b   Hall, Sara ^a,c   Surova, Yulia ^a,c   Nielsen, Henrietta M ^a,d   Janelidze, Shorena ^a   Brundin, Lena ^a,e,f   Hansson, Oskar ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b Psychiatry Research Skåne   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MAYO CLINIC   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

C reactive protein; Cerebrospinal fluid; Cytokines; Dementia; Depression; Fatigue; Neuroinflammation; Parkinson's disease

Indexed keywords

C REACTIVE PROTEIN; EOTAXIN; GAMMA INTERFERON; INTERFERON GAMMA INDUCED PROTEIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPRESSION; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL;

C-REACTIVE PROTEIN; CEREBROSPINAL FLUID; CYTOKINES; DEMENTIA; DEPRESSION; FATIGUE; NEUROINFLAMMATION; PARKINSON'S DISEASE;

AGED; C-REACTIVE PROTEIN; CHEMOKINE CCL11; CHEMOKINE CCL2; CHEMOKINE CCL24; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINES, CC; COGNITION DISORDERS; DEMENTIA; DEPRESSION; FATIGUE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PARKINSON DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883771075     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.07.007     Document Type: Article

References (54)

1. Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov. Disord. 2009, 24:2175-2186.
2. Bao A.M., Meynen G., Swaab D.F. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res. Rev. 2007, 57:531-553.
3. Barnum C.J., Tansey M.G. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog. Brain Res. 2010, 184:113-132.
4. Barnum C.J., Tansey M.G. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?. Curr. Neurol. Neurosci. Rep. 2012, 12:350-358.
5. Berczi I., Quintanar-Stephano A., Kovacs K. Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann. N. Y. Acad. Sci. 2009, 1153:220-239.
6. Blum-Degen D., Müller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimeŕs and de novo Parkinsońs disease patients. Neurosci. Lett. 1995, 202:17-20.
7. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
8. Cella, D., 1997. FACIT Manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Center on Outcomes, Research and Education, (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston, IL.
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
10. Di Napoli M., Godoy D.A., Campi V., Masotti L., Smith C.J., Parry Jones A.R., Hopkins S.J., Slevin M., Papa F., Mogoanta L., Pirici D., Popa Wagner A. C-reactive protein in intracerebral hemorrhage: time course, tissue localization, and prognosis. Neurology 2012, 79:690-699.
11. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and Parkinsonism. Acta Neurol. Scand. 1999, 100:34-41.
12. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
13. Dunn A.J. Effects of cytokines and infections on brain neurochemistry. Clin. Neurosci. Res. 2006, 6:52-68.
14. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 2007, 22:1689-1707. (quiz 1837).
15. Erhardt S., Lim C.K., Linderholm K.R., Janelidze S., Lindqvist D., Samuelsson M., Lundberg K., Postolache T.T., Traskman-Bendz L., Guillemin G.J., Brundin L. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013, 38:743-752.
16. Fahn S., Elton R.L. Members of the UPDRS Development Committee. Unified Parkinsons Disease Rating Scale. Recent Developments in Parkinsons Disease 1987, vol. 2:153-163. Macmillan Healthcare Information, Florham Park.
17. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
18. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
19. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999, 56:33-39.
20. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
21. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
22. Heesen C., Nawrath L., Reich C., Bauer N., Schulz K.H., Gold S.M. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?. J. Neurol. Neurosurg. Psychiatry 2006, 77:34-39.
23. Hinnell C., Hurt C.S., Landau S., Brown R.G., Samuel M. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease?. Mov. Disord. 2012, 27:236-241.
24. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 2000, 61(Suppl 6):4-6.
25. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
26. Holmes C., El-Okl M., Williams A.L., Cunningham C., Wilcockson D., Perry V.H. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74:788-789.
27. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
28. Juma W.M., Lira A., Marzuk A., Marzuk Z., Hakim A.M., Thompson C.S. C-reactive protein expression in a rodent model of chronic cerebral hypoperfusion. Brain Res. 2011, 1414:85-93.
29. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., Hansson O., Bjorkqvist M., Traskman-Bendz L., Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 2009, 66:287-292.
30. Lindqvist D., Kaufman E., Brundin L., Hall S., Surova Y., Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One 2012, 7:e47387.
31. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009, 33:355-366.
32. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 1995, 21:195-218.
33. McKinlay A., Grace R.C., Dalrymple-Alford J.C., Anderson T., Fink J., Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease patients without dementia. Parkinsonism Relat. Disord. 2008, 14:37-42.
34. Mehta D., Raison C.L., Woolwine B.J., Haroon E., Binder E.B., Miller A.H., Felger J.C. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav. Immun. 2013, 31:205-215.
35. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of parkinsons disease. Psychosomatics 2010, 51:474-479.
36. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
37. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
38. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211:13-16.
39. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
40. Scalzo P., Kummer A., Cardoso F., Teixeira A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 2010, 468:56-58.
41. Scalzo P., de Miranda A.S., Guerra Amaral D.C., de Carvalho Vilela M., Cardoso F., Teixeira A.L. Serum levels of chemokines in Parkinson's disease. NeuroImmunoModulation 2011, 18:240-244.
42. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:201-217.
43. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann. Neurol. 2002, 52:168-174.
44. Schwab R.S., England A.C. Projection Technique for Evaluating Surgery in Parkinson's Disease. Third Symposium of Parkinson's Disease 1969, 152-157. E&S Livingstone, Edinburgh. F.J. Gillingham, I.M.L. Donaldson (Eds.).
45. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
46. Soh S.-E., Morris M.E., McGinley J.L. Determinants of health-related quality of life in Parkinsons disease: a systematic review. Parkinsonism Relat. Disord. 2011, 17:1-9.
47. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208:1-25.
48. Vitkovic L., Bockaert J., Jacque C. "Inflammatory" cytokines: neuromodulators in normal brain?. J. Neurochem. 2000, 74:457-471.
49. Wada-Isoe K., Wakutani Y., Urakami K., Nakashima K. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol. Scand. 2004, 110:124-127.
50. Weintraub D., Morales K.H., Moberg P.J., Bilker W.B., Balderston C., Duda J.E., Katz I.R., Stern M.B. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov. Disord. 2005, 20:1161-1169.
51. Westin K., Buchhave P., Nielsen H., Minthon L., Janciauskiene S., Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012, 7:e30525.
52. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887:80-89.
53. Yeh E.T. A new perspective on the biology of C-reactive protein. Circ. Res. 2005, 97:609-611.
54. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.